Davis, California-based biotech company, Arcadia Biosciences Inc. has announced the pricing for its upcoming initial public offering (IPO) seeking to raise $100 million.

The company estimates that 7.15 million shares will be sold at between $13 and $15 per share, although a date for the float has not been set.

Since its formation in 2002, working under its broad mission to enable the production of healthier foods under marginal conditions at lower prices, Arcadia develops biotechnologies to raise crop quality, increase yields, and develop beneficial traits such as tolerance to salinity, heat, and crop treatments. To date, the company has 13 traits that have shown efficacy in field trials, and more than 50 products in development.

Arcadia has one product on the market – genetically modified, Sonova Ultra GLA Safflower Oil, which offers high levels of omega-6 fatty acids, or GLA, which has been shown to benefit weight management, skin condition, and women’s hormone balance.

Last year the company raised $33 million through a round of financing bringing its total equity investments to $101 million.

Credit Suisse Securities LLC and JP Morgan Securities LLC are leading the IPO, with Piper Jaffray & Co. acting as an additional manager for the offering.

More on this story
To receive relevant news stories with summaries provided by GAI News, subscribe to daily or weekly service.